Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21756933 | 0.84 | GABRA1 (0.41) | GABRA1GABRB1GABRB2GAAALDH1A1 | |
| SCHEMBL12197671 | 0.80 | GABRA1 (0.52) | GABRA1GABRB1GABRB2HIF1ASLC6A2 | |
| SCHEMBL29433029 | 0.78 | CASP1 (0.42) | GAAALDH1A1HIF1AALOX12HTT | |
| SCHEMBL33893 | 0.78 | CASP1 (0.42) | GAAALDH1A1HIF1AALOX12HTT | |
| SCHEMBL13818840 | 0.78 | GABRA1 (0.50) | GABRA1GABRB1GABRB2HIF1ASLC6A2 | |
| SCHEMBL2155134 | 0.78 | ALDH1A1 (0.48) | GAAALDH1A1HIF1AALOX12HTT | |
| SCHEMBL28252731 | 0.78 | CASP1 (0.42) | GAAALDH1A1HIF1AALOX12HTT | |
| SCHEMBL4799932 | 0.77 | SLC6A4 (0.33) | GABRA1GABRB1GABRB2GAAALDH1A1 | |
| SCHEMBL24632260 | 0.76 | GABRA1 (0.33) | GABRA1GABRB1GABRB2HIF1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL10534032 | 0.76 | CASP1 (0.41) | GAAALDH1A1HIF1AALOX12HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4479040-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2024-12-25 | — | — | EP | disclosed |
| CN-119136796-A | Neurotensin receptor-targeting compounds and radioligands and uses thereof | 辐联科技香港有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-12145926-B2 | Compounds and radioligands for targeting neurotensin receptor and uses thereof | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-11-19 | — | — | US | disclosed |
| US-20240287046-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-08-29 | — | — | US | disclosed |
| WO-2023158802-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES U.S. INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158802-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES U.S. INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2020245297-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ALMIRALL, S.A. (ES) | 2020-12-10 | — | — | WO | disclosed |
| CN-1863789-B | Substituted isoquinolinones | PORTOLA PHARM INC | 2010-06-09 | — | — | CN | disclosed |
| EP-1667989-A4 | SUBSTITUTED ISOQUINOLINONES | PORTOLA PHARM INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7294635-B2 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| CN-1863789-A | Substituted isoquinolinones | PORTOLA PHARM INC (US) | 2006-11-15 | — | — | CN | disclosed |
| EP-1667989-A1 | SUBSTITUTED ISOQUINOLINONES | Portola Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050113399-A1 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005035520-A1 | SUBSTITUTED ISOQUINOLINONES | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | DIXON BRIAN R (US) | 2003-11-06 | — | — | US | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-1144396-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | Bayer Corporation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| US-4710507-A | Quinolone inotropic agents | PFIZER INC. (US) | 1987-12-01 | — | — | US | disclosed |
| EP-0148623-A2 | Quinolone inotropic agents | Pfizer Limited (GB) | 1985-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113399-A1 | Substituted isoquinolinones | PFKP, MPL, TBXA2R | GABRA1 2249/4885GABRB1 3164/4885GABRB2 3089/4885 |
| US-20240287046-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | NTSR1, NTSR2, NPSR1 | GABRA1 442/4885GABRB1 719/4885GABRB2 746/4885 |
| US-12145926-B2 | Compounds and radioligands for targeting neurotensin receptor and uses thereof | NTSR1, NTSR2, NPSR1 | GABRA1 442/4885GABRB1 719/4885GABRB2 746/4885 |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | PGR, PGRMC2, PGRMC1 | GABRA1 357/4885GABRB1 288/4885GABRB2 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.